BAM-15
Also known as: BAM15, Mitochondrial protonophore
Mitochondrial Uncoupler | Metabolic Enhancer
Overview
BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.
Key benefits
- Increases fat oxidation without affecting food intake
- Reduces body fat mass in research models
- 7-fold more potent than DNP with better safety
- Does not cause dangerous hyperthermia
- No effect on lean body mass
- Improves insulin sensitivity
- Orally bioavailable
- Activates AMPK and PGC-1α pathways
- Synergistic with GLP-1 agonists (semaglutide)
Mechanism of action
BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.
Molecular data
- Type
- Small molecule (not a peptide)
- Half-life
- ~1.7 hours
Sequence
C16H10F2N6O
Indications
What the research community uses this compound for, with self-reported effectiveness.
Metabolic Research
Obesity/Fat Loss
EffectiveReduces body fat by increasing energy expenditure and fat oxidation without reducing food intake.
Insulin Resistance
EffectiveResearch shows reversal of diet-induced insulin resistance in mouse models.
Metabolic Syndrome
ModerateAddresses multiple components of metabolic syndrome through enhanced energy expenditure.
Combination Therapy Research
With Semaglutide/GLP-1 Agonists
Effective2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation.
Caloric Restriction Enhancement
ModerateMay help overcome weight loss plateaus by preventing metabolic adaptation/efficiency.
Other Research Areas
Liver Triglycerides
ModerateResearch shows decreased liver triglycerides in treated animals.
Glucose Tolerance
ModerateImproved glucose tolerance observed in research models.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Oral
BAM-15 is orally bioavailable and is typically administered as an oral supplement in tablet or capsule form. Research in mice used dietary supplementation (0.1% of diet) or oral gavage dosing. Human dosing protocols are still being established through ongoing research. The compound has a relatively short half-life, which researchers are working to improve through structural modifications.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Metabolic enhancement | 25-50 mg | Once or twice daily | Oral |
| Research protocol (mouse equivalent) Based on animal research; human doses extrapolated | ~10 mg/kg | Daily | Oral gavage |
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
DNP/FCCP
AvoidDo not combine with other mitochondrial uncouplers - dangerous additive effects possible.
Thyroid hormones
MonitorBoth increase metabolic rate; combination requires careful monitoring.
Semaglutide/GLP-1 Agonists
Synergistic2024 research shows combination produces stronger metabolic benefits by countering metabolic adaptation that limits GLP-1 efficacy.
Tirzepatide
SynergisticSimilar synergy expected as with semaglutide; helps overcome weight loss plateaus.
MOTS-c
CompatibleBoth affect mitochondrial function but through different mechanisms.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Hours
Increased oxygen consumption and metabolic rate
- Days 1-7
Shift toward fat oxidation (lower respiratory exchange ratio)
- Weeks 2-4
Measurable fat mass reduction in research
- Weeks 4-8
Improved insulin sensitivity and glucose tolerance
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated in research
- Possible mild increase in body temperature (less than DNP)
Rare side effects
- Unknown in humans (limited clinical data)
- Theoretical GI disturbance
Stop signs — stop and seek advice
- Significant hyperthermia/overheating
- Excessive sweating
- Rapid heart rate
- Difficulty breathing
Contraindications
- Hyperthyroidism or thyroid disorders
- Heart conditions
- Pregnancy or breastfeeding
- Use of other mitochondrial uncouplers (DNP, FCCP)
- Fever or active infection
Monitoring
- Body temperature
- Heart rate
- Energy levels
- No clinical monitoring protocols established yet
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- White to off-white powder or tablets
- Certificate of analysis with purity >98%
- Proper packaging protected from light
- Reputable supplier
Warning signs
- No third-party testing available
- Unclear sourcing
Stop signs — don't use
- Discolored product
- No purity information
- Unknown origin
References
Primary literature and clinical-trial data informing this entry.
Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice
Nature Communications · 2020
BAM15 is orally bioavailable, increases nutrient oxidation, decreases body fat mass without altering food intake, lean mass, body temperature, or markers of toxicity.
BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control
EMBO Molecular Medicine · 2020
BAM15 is 7-fold more potent than DNP, does not depolarize plasma membranes, and does not induce apoptosis at effective doses.
BAM15 as a mitochondrial uncoupler: a promising therapeutic agent for diverse diseases
PMC Review · 2023
Comprehensive review of BAM15 mechanisms including AMPK and PGC-1α activation pathways.
Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice
Clinical Science · 2024
Combining semaglutide and BAM15 produces stronger metabolic benefits than either alone; helps overcome metabolic adaptation.
Last updated . How this page was sourced is described in the methodology.